Advertisement

European society of medical oncology (ESMO) 2019 meeting report features practice changing data in gynecologic malignancies

Published:January 05, 2020DOI:https://doi.org/10.1016/j.ygyno.2019.11.010

      Abstract

      Multiple practice changing studies were presented at the 2019 ESMO Congress in Barcelona, Spain. The ovarian cancer studies presented at the Presidential session will likely refine and redefine the initial treatment of ovarian cancer. Other compelling trial data in ovarian, uterine and cervical cancer were also unveiled. The key oral abstracts from this meeting are summarized in this meeting report.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Gynecologic Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Ray-Coquard I.L.
        • Pautier P.
        • Pignata S.
        • Pérol D.
        • González-Martín A.
        • Sevelda P.
        • Fujiwara K.
        • Vergote I.B.
        • Colombo N.
        • Mäenpää J.
        • Selle F.
        • Sehouli J.
        • Lorusso D.
        • Alia E.M.G.
        • Lefeuvre-Plesse C.
        • Canzler U.
        • Lortholary A.
        • Marmé F.
        • Pujade-Lauraine E.
        • Harter P.
        LBA2_PR Phase III PAOLA-1/ENGOT-ov25 trial: olaparib plus bevacizumab (bev) as maintenance therapy in patients (pts) with newly diagnosed, advanced ovarian cancer (OC) treated with platinum-based chemotherapy (PCh) plus bev.
        N. Engl. J. Med. 2019 Dec 19; 381: 2416-2428https://doi.org/10.1056/NEJMoa1911361
        • Gonzalez-Martin A.
        • Pothuri B.
        • Vergote I.
        • DePont Christensen R.
        • Graybill W.
        • Mirza M.R.
        • McCormick C.
        • Lorusso D.
        • Hoskins P.
        • Freyer G.
        • Baumann K.
        • Jardon K.
        • Redondo A.
        • Moore R.G.
        • Vulsteke C.
        • O’Cearbhaill R.E.
        • Lund B.
        • Backes F.
        • Barretina-Ginesta P.
        • Haggerty A.F.
        • Rubio-Perez M.J.
        • Shahin M.S.
        • Mangili G.
        • Bradley W.H.
        • Bruchim I.
        • Sun K.
        • Malinowska I.A.
        • Li Y.
        • Gupta D.
        • Monk B.J.
        Investigators PE-OG-. Niraparib in patients with newly diagnosed advanced ovarian cancer.
        N. Engl. J. Med. 2019; https://doi.org/10.1056/NEJMoa1909707
        • Coleman R.L.
        • Fleming G.F.
        • Brady M.F.
        • Swisher E.M.
        • Steffensen K.D.
        • Friedlander M.
        • Okamoto A.
        • Moore K.N.
        • Efrat Ben-Baruch N.
        • Werner T.L.
        • Cloven N.G.
        • Oaknin A.
        • DiSilvestro P.A.
        • Morgan M.A.
        • Nam J.H.
        • Leath 3rd, C.A.
        • Nicum S.
        • Hagemann A.R.
        • Littell R.D.
        • Cella D.
        • Baron-Hay S.
        • Garcia-Donas J.
        • Mizuno M.
        • Bell-McGuinn K.
        • Sullivan D.M.
        • Bach B.A.
        • Bhattacharya S.
        • Ratajczak C.K.
        • Ansell P.J.
        • Dinh M.H.
        • Aghajanian C.
        • Bookman M.A.
        Veliparib with first-line chemotherapy and as maintenance therapy in ovarian cancer.
        N. Engl. J. Med. 2019; https://doi.org/10.1056/NEJMoa1910962
        • Gershenson D.M.
        • Miller A.
        • Brady W.
        • Paul J.
        • Carty K.
        • Rodgers W.
        • Millan D.
        • Coleman R.L.
        • Moore K.N.
        • Banerjee S.
        • Connolly K.
        • Secord A.A.
        • O’Malley D.M.
        • Dorigo O.
        • Gaillard S.
        • Gabra H.
        • Hanjani P.
        • Huang H.
        • Wenzel L.
        • Gourley C.
        LBA61A randomized phase II/III study to assess the efficacy of trametinib in patients with recurrent or progressive low-grade serous ovarian or peritoneal cancer.
        Ann. Oncol. 2019; 30
        • Grisham R.
        • Monk J.B.
        • Banerjee S.
        • Coleman L.R.
        • Oza M.A.
        • Oehler K.M.
        • Kalbacher E.
        • Mirza Raza M.
        • del Campo M.J.
        • Marth C.
        • Westermann A.
        • Pignata S.
        • Colombo N.
        • Cibula D.
        • Hilpert F.
        • Aghajanian C.
        • Drill E.
        • Sandor V.
        • Boyd P.A.
        • Vergote I.
        1 MILO/ENGOT-OV11: phase-3 study of binimetinib versus physician’s choice chemotherapy (PCC) in recurrent or persistent low-grade serous carcinomas of the ovary, fallopian tube, or primary peritoneum.
        Int. J. Gynecol. Cancer. 2019; 29 (A1-A1)
        • Le D.T.
        • Durham J.N.
        • Smith K.N.
        • Wang H.
        • Bartlett B.R.
        • Aulakh L.K.
        • Lu S.
        • Kemberling H.
        • Wilt C.
        • Luber B.S.
        • Wong F.
        • Azad N.S.
        • Rucki A.A.
        • Laheru D.
        • Donehower R.
        • Zaheer A.
        • Fisher G.A.
        • Crocenzi T.S.
        • Lee J.J.
        • Greten T.F.
        • Duffy A.G.
        • Ciombor K.K.
        • Eyring A.D.
        • Lam B.H.
        • Joe A.
        • Kang S.P.
        • Holdhoff M.
        • Danilova L.
        • Cope L.
        • Meyer C.
        • Zhou S.
        • Goldberg R.M.
        • Armstrong D.K.
        • Bever K.M.
        • Fader A.N.
        • Taube J.
        • Housseau F.
        • Spetzler D.
        • Xiao N.
        • Pardoll D.M.
        • Papadopoulos N.
        • Kinzler K.W.
        • Eshleman J.R.
        • Vogelstein B.
        • Anders R.A.
        • Diaz Jr., L.A.
        Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.
        Science. 2017; 357: 409-413
        • KEYTRUDA® F.D.A.
        (pembrolizumab) injection, for intravenous use Initial U.S. Approval.
        (Accessed)
        • McMeekin D.S.
        • Tritchler D.L.
        • Cohn D.E.
        • Mutch D.G.
        • Lankes H.A.
        • Geller M.A.
        • Powell M.A.
        • Backes F.J.
        • Landrum L.M.
        • Zaino R.
        • Broaddus R.D.
        • Ramirez N.
        • Gao F.
        • Ali S.
        • Darcy K.M.
        • Pearl M.L.
        • DiSilvestro P.A.
        • Lele S.B.
        • Goodfellow P.J.
        Clinicopathologic significance of mismatch repair defects in endometrial cancer: an NRG oncology/gynecologic oncology group study.
        J. Clin. Oncol. 2016; 34: 3062-3068
        • O’Malley D.
        • Marabelle A.
        • De Jesus-Acosta A.
        • Piha-Paul S.A.
        • Arkhipov A.
        • Longo F.
        • Motola-Kuba D.
        • Shapira-Frommer R.
        • Geva R.
        • Rimel B.J.
        • Lopez-Martin J.A.
        • Hansen A.R.
        • Mehnert J.M.
        • Chen X.
        • Jin F.
        • Norwood K.
        • Ott P.A.
        1044P Pembrolizumab in patients with MSI-H advanced endometrial cancer from the KEYNOTE-158 study.
        Ann. Oncol. 2019; 30
        • Ott P.A.
        • Bang Y.J.
        • Berton-Rigaud D.
        • Elez E.
        • Pishvaian M.J.
        • Rugo H.S.
        • Puzanov I.
        • Mehnert J.M.
        • Aung K.L.
        • Lopez J.
        • Carrigan M.
        • Saraf S.
        • Chen M.
        • Soria J.C.
        Safety and antitumor activity of pembrolizumab in advanced programmed death ligand 1-positive endometrial cancer: results from the KEYNOTE-028 study.
        J. Clin. Oncol. 2017; 35: 2535-2541
        • Vergote I.
        • Teneriello M.
        • Powell M.A.
        • Miller D.S.
        • Garcia A.A.
        • Mikheeva O.N.
        • Pinter T.
        • Bidzinski M.
        • Cebotaru C.L.
        • Fan J.
        • Ren M.
        • Meneses N.
        • Funahashi Y.
        • Kadowaki T.
        • O’Brien J.P.
        • Penson R.T.
        A phase II trial of lenvatinib in patients with advanced or recurrent endometrial cancer: angiopoietin-2 as a predictive marker for clinical outcomes.
        J. Clin. Oncol. 2013; 31 (5520-5520)
        • Makker V.
        • Rasco D.
        • Vogelzang N.J.
        • Brose M.S.
        • Cohn A.L.
        • Mier J.
        • Di Simone C.
        • Hyman D.M.
        • Stepan D.E.
        • Dutcus C.E.
        • Schmidt E.V.
        • Guo M.
        • Sachdev P.
        • Shumaker R.
        • Aghajanian C.
        • Taylor M.
        Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial.
        Lancet Oncol. 2019; 20: 711-718
        • Makker V.
        • Taylor M.H.
        • Aghajanian C.
        • Oaknin A.
        • Mier J.
        • Cohn A.L.
        • Marin M.R.
        • Lorenzo R.B.
        • Brose M.S.
        • DiSimone C.
        • Messing M.J.
        • Stepan D.E.
        • Dutcus C.E.
        • Wu J.
        • Schmidt E.V.
        • Orlowski R.J.
        • Sachdev P.
        • Shumaker R.
        • Herraez A.C.
        994O Lenvatinib (LEN) and pembrolizumab (PEMBRO) in advanced endometrial cancer (EC).
        Ann. Oncol. 2019; 30
        • de Boer S.M.
        • Powell M.E.
        • Mileshkin L.
        • Katsaros D.
        • Bessette P.
        • Haie-Meder C.
        • Ottevanger P.B.
        • Ledermann J.A.
        • Khaw P.
        • Colombo A.
        • Fyles A.
        • Baron M.H.
        • Jurgenliemk-Schulz I.M.
        • Kitchener H.C.
        • Nijman H.W.
        • Wilson G.
        • Brooks S.
        • Carinelli S.
        • Provencher D.
        • Hanzen C.
        • Lutgens L.
        • Smit V.
        • Singh N.
        • Do V.
        • D’Amico R.
        • Nout R.A.
        • Feeney A.
        • Verhoeven-Adema K.W.
        • Putter H.
        • Creutzberg C.L.
        • group Ps
        Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial.
        Lancet Oncol. 2018; 19: 295-309
        • Cancer Genome Atlas Research N.
        • Kandoth C.
        • Schultz N.
        • Cherniack A.D.
        • Akbani R.
        • Liu Y.
        • Shen H.
        • Robertson A.G.
        • Pashtan I.
        • Shen R.
        • Benz C.C.
        • Yau C.
        • Laird P.W.
        • Ding L.
        • Zhang W.
        • Mills G.B.
        • Kucherlapati R.
        • Mardis E.R.
        • Levine D.A.
        Integrated genomic characterization of endometrial carcinoma.
        Nature. 2013; 497: 67-73
        • Chung H.C.
        • Ros W.
        • Delord J.P.
        • Perets R.
        • Italiano A.
        • Shapira-Frommer R.
        • Manzuk L.
        • Piha-Paul S.A.
        • Xu L.
        • Zeigenfuss S.
        • Pruitt S.K.
        • Leary A.
        Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: results from the phase II KEYNOTE-158 study.
        J. Clin. Oncol. 2019; 37: 1470-1478
        • Naumann R.W.
        • Hollebecque A.
        • Meyer T.
        • Devlin M.J.
        • Oaknin A.
        • Kerger J.
        • Lopez-Picazo J.M.
        • Machiels J.P.
        • Delord J.P.
        • Evans T.R.J.
        • Boni V.
        • Calvo E.
        • Topalian S.L.
        • Chen T.
        • Soumaoro I.
        • Li B.
        • Gu J.
        • Zwirtes R.
        • Moore K.N.
        Safety and efficacy of nivolumab monotherapy in recurrent or metastatic cervical, vaginal, or vulvar carcinoma: results from the phase I/II CheckMate 358 trial.
        J. Clin. Oncol. 2019; : JCO1900739
        • Gibney G.T.
        • Weiner L.M.
        • Atkins M.B.
        Predictive biomarkers for checkpoint inhibitor-based immunotherapy.
        Lancet Oncol. 2016; 17: e542-e551
        • Gu X.
        • Shi Y.
        1054P Prognostic and clinicopathological significance of PD-L1 in patients with cervical cancer: a meta-analysis.
        Ann. Oncol. 2019; 30
        • Naumann R.W.
        • Oaknin A.
        • Meyer T.
        • Lopez-Picazo J.M.
        • Lao C.
        • Bang Y.-J.
        • Boni V.
        • Sharfman W.H.
        • Park J.C.
        • Devriese L.A.
        • Harano K.
        • Chung C.H.
        • Topalian S.L.
        • Zaki K.
        • Chen T.
        • Gu J.
        • Li B.
        • Barrows A.
        • Horvath A.
        • Moore K.N.
        LBA62 Efficacy and safety of nivolumab (Nivo) + ipilimumab (Ipi) in patients (pts) with recurrent/metastatic (R/M) cervical cancer: results from CheckMate 358.
        Ann. Oncol. 2019; 30
        • Moore K.
        • Colombo N.
        • Scambia G.
        • Kim B.G.
        • Oaknin A.
        • Friedlander M.
        • Lisyanskaya A.
        • Floquet A.
        • Leary A.
        • Sonke G.S.
        • Gourley C.
        • Banerjee S.
        • Oza A.
        • Gonzalez-Martin A.
        • Aghajanian C.
        • Bradley W.
        • Mathews C.
        • Liu J.
        • Lowe E.S.
        • Bloomfield R.
        • DiSilvestro P.
        Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer.
        N. Engl. J. Med. 2018; 379: 2495-2505
        • Burger R.A.
        • Brady M.F.
        • Bookman M.A.
        • Fleming G.F.
        • Monk B.J.
        • Huang H.
        • Mannel R.S.
        • Homesley H.D.
        • Fowler J.
        • Greer B.E.
        • Boente M.
        • Birrer M.J.
        • Liang S.X.
        • Gynecologic Oncology G.
        Incorporation of bevacizumab in the primary treatment of ovarian cancer.
        N. Engl. J. Med. 2011; 365: 2473-2483
        • Colombo N.
        • Nicoletto M.O.
        • Benedetti Panici P.
        • Tognon G.
        • Bologna A.
        • Lissoni A.A.
        • DeCensi A.
        • Tomao F.
        • Fossati R.
        • Tettamanzi F.
        • Rulli E.
        • Galli F.
        • De Luca M.
        • Alvisi M.F.
        • Mancari R.
        • Ratti M.
        • Baldoni A.
        • Torri V.
        • Biagioli E.
        LBA58 barocco: a randomized phase II study of weekly paclitaxel vs cediranib-olaparib combination given with continuous or intermittent schedule in patients with recurrent platinum resistant ovarian cancer (PROC).
        Ann. Oncol. 2019; 30
        • Konstantinopoulos P.A.
        • Wahner Hendrickson A.E.
        • Penson R.T.
        • Doyle A.
        • Kohn E.C.
        • Duska L.R.
        • Crispens M.A.
        • Olawaiye A.B.
        • Winer I.S.
        • Barroilhet L.M.
        • Fu S.
        • McHale M.T.
        • Schilder R.J.
        • Farkkila A.
        • Curtis J.
        • Quinn R.
        • Whalen C.
        • Shapiro G.I.
        • Matulonis U.A.
        LBA60 Randomized phase II (RP2) study of ATR inhibitor M6620 in combination with gemcitabine versus gemcitabine alone in platinum-resistant high grade serous ovarian cancer (HGSOC).
        Ann. Oncol. 2019; 30
        • Banerjee S.
        • Lewsley L.-A.
        • Clamp A.R.
        • krell J.
        • Herbertson R.
        • Glasspool R.M.
        • Orbegoso C.
        • Green C.
        • Kristeleit R.S.
        • Gourley C.
        • Cambell C.
        • Banerji U.
        • Shepherd C.
        • Brugger W.
        • Chudleigh L.
        • Hanif A.
        • McNeish I.A.
        • Paul J.
        993O OCTOPUS: a randomised, multi-centre phase II umbrella trial of weekly paclitaxel+/- novel agents in platinum-resistant ovarian cancer: Vistusertib.
        Ann. Oncol. 2019; 30
        • Moore K.
        • Oza A.
        • Colombo N.
        • Oaknin A.
        • Scambia G.
        • Lorusso D.
        • Farias-Eisner R.
        • Banerjee S.
        • Murphy C.
        • Tanyi J.
        • Hirte H.
        • Konner J.
        • Lim P.
        • Hayes M.P.
        • Monk B.
        • Kim S.
        • Wang J.
        • Pautier P.
        • Vergote I.
        • Birrer M.
        992O forward I (GOG 3011): a phase III study of mirvetuximab soravtansine, a folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC), versus chemotherapy in patients (pts) with platinum-resistant ovarian cancer (PROC).
        Ann. Oncol. 2019; 30